892863-69-3

Upstream product

• 159660-85-2 1-benzyl-4-aminotetrahydropyridine-3-carboxylic acid methyl ester 
• 70336-83-3 methyl 4-amino-1-benzyl-1,2,5,6-tetrahydropyridine-3-carboxylate 

Downstream Products

• 1253191-32-0 1-benzyl-N-cyclopropyl-N-(2,3-dichlorobenzyl)-4-(4-(2-(2,6-dichlorophenoxy)ethoxy)benzamido)piperidine-3-carboxamide 
• 1253191-31-9 1-benzyl-4-(4-(2-(2,6-dichlorophenoxy)ethoxy)benzamido)piperidine-3-carboxylic acid 
• 1253191-30-8 ethyl 1-benzyl-4-(4-(2-(2,6-dichlorophenoxy)ethoxy)benzamido) piperidine-3-carboxylate 

Relevant academic research and scientific papers

ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY

The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

Synthesis of new trisubstituted 4-aminopiperidines as PAF-receptor antagonists

Two novel classes of 4-aminopiperidines substituted in the 3-position by groups bearing either a carbamate or a ureido function have been synthesized from ethyl 4-oxo-3-piperidinecarboxylate and 3,3′-iminobis(propanenitrile) , respectively. The key step in this synthesis, the reduction of the piperidinic β-enamino ester or nitrile, occurred readily. In contrast to published works, the free primary amines could be isolated from the corresponding β-amino ester or nitrile. Regioselective amidification of the amino group offered two pairs of diastereoisomers which were successfully separated and identified. Measurement of PAF-receptor antagonist activity gave interesting results with an IC50 close to the micromolar. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

4-Aminopiperidine derivatives

The present invention relates to compounds of the formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or β-cell protection.